Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-Ranging Prasugrel Pharmacokinetics in Pediatric Sickle Cell Disease
2017-001243-12Phase 2
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of prasugrel in sickle cell disease (SCD), sponsored by Eli Lilly and Company. Primary endpoint: Area Under the Concentration-Time Curve (AUC) of Prasugrel Active Metabolite (Pras-AM).
02
Drugs
prasugrel
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on 2017-001243-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001243-12.